Introduction: Cancer cells apply various mechanisms to induce and enhance immune
escape. The complex network of immune-response modulating factors in the tumor …

The tumor microenvironment (TME) plays an essential role in the development, growth, and
survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL). Within the …

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting
Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative …

The efficacy of conventional anti-tumor immunotherapeutic approaches is markedly affected
by the immunosuppressive microenvironment of tumor. Since adenosine is one of the main …

Maternal immune system must tolerate semiallogenic fetus to establish and maintain a
successful pregnancy. Despite the existence of several strategies of trophoblast to avoid …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a wide range of
tumor-induced alterations, which affect both the innate and adaptive arms of the immune …

The immunosuppressive state of the tumor microenvironment diminishes the efficacy of
dendritic cell (DC)-based cancer immunotherapy. Inhibitory immune checkpoint molecules …

Chronic lymphocytic leukemia (CLL) is a malignancy of mature, antigen-experienced B
lymphocytes. Despite great progress recently achieved in the management of CLL, the …

Abstract Background Ibrutinib is a Bruton's tyrosine kinase (BTK) and interleukin-2-inducible
kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other …

Despite developments in the treatment of various cancers, prostate cancer is one of the
deadliest diseases known to men. Systemic therapies such as androgen deprivation …